Drugs / CS1-BCMA CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04662099 | Mar 2020 → Dec 2023 | indolent plasma cell myeloma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS1\&BCMA CAR T cells | “This study aims to evaluate prelimary safety and efficacy of the CS1\&BCMA CAR T cells in patients with relapsed or refractory MM.” NCT04662099 ↗1“Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.” PMID 37848634 ↗ Oct 2023 |
| Action | Deplete | “The bispecific CAR T cells have exhibited potent cytotoxicity in various BCMA+ or/and CS1+ MM cells and can effectively eradicate MM cells in xenograft mice models.” NCT04662099 ↗ |
| Modality | Cell therapy | “Here we constructed bispecific CS1-BCMA CAR-T cells aiming to augment BCMA targeting with CS1.” PMID 37848634 ↗ Oct 2023 |